UNSPSC 51161547: Motapizone

This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H12N4OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4A61P8A37, chemically known as 3(2h)-pyridazinone, 4,5-dihydro-6-(4-imidazol-1-yl-2-thienyl)-5-methyl- but generally known as motapizone, which bears US NIH Compound Identifier 65819. European Medicines Agency schedules Motapizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09075MIG.

UNSPSC 51161547 Motapizone, a Commodity code, encompasses generic multi-source pharmaceuticals and over-the-counter products that state and local governments procure through cooperative purchasing vehicles and direct supply arrangements. State and local health departments, correctional facilities, and other public health agencies buy under this code to stock medication inventories and distribute products across their service populations. The issuing bodies are primarily state health and human services departments participating in multi-state cooperative purchasing alliances, along with subordinate county and municipal health clinics and correctional institutions that draw on centralized pharmaceutical contracts.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The solicitation requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with all products available by May 15, 2026 and resulting contracts effective July 1, 2026. Evaluation is weighted heavily on price competitiveness (75 percent), with secondary weight on fixed pricing (10 percent) and compliance with administrative, EDI, and fee-agreement requirements (5 percent each). Vendors must certify cGMP and DSCSA compliance, maintain relationships with at least two of the three authorized wholesalers, and carry commercial general liability coverage of $5,000,000 per occurrence. The contract term is two years for new responders with optional extensions, while incumbent responders' amendments run through June 30, 2028.